CDC - GISP Profiles - 2015

CDC - GISP Profiles - 2015

Gonococcal Isolate Surveillance Project (GISP) Profiles, 2015

Site Specific Profiles

 Select Albuquerque, New Mexico Atlanta, Georgia Birmingham, Alabama Boston, Massachusetts Buffalo, New York Chicago, Illinois Cleveland, Ohio Columbus, Ohio Dallas, Texas Greensboro, North Carolina Honolulu, Hawaii Indianapolis, Indiana Kansas City, Missouri Las Vegas, Nevada Los Angeles, California Minneapolis, Minnesota New Orleans, Louisiana New York City, New York Orange County, California Philadelphia, Pennsylvania Phoenix, Arizona Pontiac, Michigan Portland, Oregon San Diego, California San Francisco, California Seattle, Washington Tripler Army Medical Center, Hawaii 
 

 Summaries – All Sites

Figure A – Age of GISP Participants, in Years

Figure B – Race/Ethnicity of GISP Participants

Figure C – Percentage of GISP Participants Identifying as Men Who Have Sex with Men, 2000-2015

Figure D – Primary Antimicrobial Drug Used to Treat Gonorrhea among GISP Participants

Figure E – Secondary Antimicrobial Drug Used to Treat Gonorrhea among GISP Participants

Figure F – Percentage of isolates with Penicillin, Tetracycline, and Ciprofloxacin Resistance

Figure G – Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) among GISP Isolates, 2011-2015

Figure H – Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) among GISP Isolates, 2011-2015

Figure I – Percentage of Isolates with Intermediate Resistance or Resistance to ciprofloxacin, 2000-2015

Figure J – Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) among GISP Isolates, 2011-2015

The Gonococcal Isolate Surveillance Project (GISP), a national sentinel surveillance system, was established in 1986 to monitor trends in antimicrobial susceptibilities of Neisseria gonorrhoeae strains in the United States among selected sexually transmitted diseases (STD) clinics in approximately 25-30 GISP sentinel sites.

Annual reports were published for the years 1998–2007. Starting in 2008, site-specific GISP profiles have been published online each year.

The following site-specific profiles consist of figures depicting the demographic and clinical data of the men with gonorrhea enrolled in GISP and the antimicrobial susceptibility results of the Neisseria gonorrhoeae isolates submitted.

GISP Profiles 2015 Introduction, Text, Figures, Tables and all Profiles[PDF – 3 MB]

Figure 1. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among Neisseria gonorrhoeaeIsolates, Gonococcal Isolate Surveillance Project (GISP), 2011-2015

Figure 2. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance Project (GISP), 2011-2015

Figure 3. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance Project (GISP), 2011-2015

Figure 4. Percentage of Neisseria gonorrhoeae Isolates that are Ciprofloxacin-Resistant by Reported Sex of Sex Partner, Gonococcal Isolate Surveillance Project, 1995-2015

Table 1. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among Neisseria gonorrhoeaeIsolates, Gonococcal Isolate Surveillance Project, 2011–2015

Table 2. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance Project, 2011–2015

Table 3. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among Neisseria gonorrhoeae Isolates, Gonococcal Isolate Surveillance Project, 2011–2015

Related Content

•  All Years GISP Profiles and Annual Reports
• 2015 STD Surveillance Report – Gonorrhea
• More information about GISP